What’s the current market cap for Lineage Cell Therapeutics stock?

Lineage Cell Therapeutics (LCTX) has a market cap of $324M as of May 24, 2026.

What is the P/E ratio for Lineage Cell Therapeutics stock?

The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of May 24, 2026.

Does Lineage Cell Therapeutics stock pay dividends?

No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of May 24, 2026.

When is the next Lineage Cell Therapeutics dividend payment date?

Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) does not currently have a Beta indicator.

Buy Lineage Cell Therapeutics stock | $LCTX Share Price

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Ticker

$LCTX

Sector

Health

Primary listing

AMEX

Employees

75

Headquarters

Carlsbad, United States

Website

www.lineagecell.com

LCTX Metrics

BasicAdvanced

$324m

-

-$0.28

-

What the Analysts think about LCTX

Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.

Bulls say / Bears say

Reached the first milestone in the $620 million Roche/Genentech partnership for OpRegen, which validates the AlloSCOPE manufacturing platform and brings in non-dilutive funding to support clinical programs.

Reported positive 36-month Phase 1/2a data for OpRegen at CTS 2025, showing lasting improvements in visual acuity and retinal structure from just one treatment, positioning OpRegen as a leading therapy for geographic atrophy.

Ended 2025 with $55.8 million in cash, cash equivalents, and marketable securities, plus $5.4 million from warrant proceeds, extending funding runway into Q2 2028 and lowering near-term financing risks.

Net loss for full year 2025 widened to $63.5 million from $18.6 million in 2024, mainly due to non-cash fair value adjustments for warrant liabilities and impairment charges. This highlights significant financial volatility and exposure to accounting-driven expenses.

Operating expenses jumped to $51.2 million in 2025 from $31.0 million the year before, largely from higher R&D spending and a $14.8 million impairment on the VAC platform, which could strain the company's cash reserves and delay profitability.

Full year 2025 revenues were $14.6 million, still modest and primarily from milestone and collaboration payments tied to the Roche/Genentech and WDI deals. This could result in uneven cash flow and increased execution risk if future milestones are postponed.

Data summarised monthly by Lightyear AI. Last updated on 3 May 2026.

LCTX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

LCTX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

LCTX News

AllArticlesVideos

Lineage Cell Therapeutics Q1 Earnings Call Highlights

MarketBeat·1 week ago

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Business Wire·2 weeks ago

Lineage Announces Formation of Scientific Advisory Board

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.